CBSET data disclosed at Cardiovascular Research Technologies (CRT) 2015 LEXINGTON, Mass., Feb 25, 2015 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today that its scientists have defined the optimal tissue debulking protocol for treating in-stent restenosis (ISR) with Boston Scientific’s JETSTREAM® Navitus […]
Elazer R. Edelman, M.D., Ph.D., presents ex vivo results at Cardiovascular Research Technologies (CRT) 2015 LEXINGTON, Mass., Feb 23, 2015 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, disclosed today that modification of atherosclerotic plaque with the Diamondback 360® orbital atherectomy device (Cardiovascular Systems, […]
LEXINGTON, Mass., Dec 11, 2014— CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today that it has appointed Haim Danenberg, M.D., as chief scientific adviser, effective immediately. Prof. Danenberg has served as Head of the Cardiovascular Research Center and Director of Interventional Cardiology at the Heart […]
“Confounding data from recent clinical trials must not deter industry. Sympathetic denervation and neuromodulation techniques still provide an exciting opportunity for the treatment of resistant hypertension and of a variety of other diseases. The current device therapies are still in their infancy, and the rate of technological advancement in this field is accelerating exponentially.Our preclinical […]
“Sympathetic denervation remains an exciting therapy for a range of diseases but is currently plagued by clinical variability. CBSET is aiming to provide mechanistic data as a pathway to improve future efficacy.” – Peter M. Markham, President and CEO, CBSET LEXINGTON, Mass., May 16, 2014 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical […]
March 27, 2014 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational, comprehensive preclinical evaluation and optimization of renal denervation devices that can be utilized […]
“CBSET has previously reported scientific data predicting lesion geometry following radiofrequency (RF) renal denervation treatment in preclinical models. Now, we encourage the industry to invest in further, mechanistic research to develop next-generation devices that more precisely and selectively deliver RF or other types of energy to the nerve-rich tissue compartments surrounding the renal artery wall.” […]
“We are committed to investing in state-of-the-art technologies that advance the most effective preclinical science for our Sponsors” – Peter M. Markham, President and CEO, CBSET LEXINGTON, Mass., November 19, 2013 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, has expanded its preclinical development capabilities with the installation […]
October 28, 2013 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, will present data from the podium at the Transcatheter Cardiovascular Therapeutics annual scientific meeting (TCT 2013) that provides a seminal experimental and computational template for a more rational, comprehensive preclinical evaluation and optimization of renal […]
“We will report a breakthrough: an experimental computational methodology for understanding and predicting lesion geometry following radiofrequency (RF) renal denervation treatment to lower hypertension. We expect that our research will have a significant effect on the development of devices that will be able to more precisely and selectively deliver RF or other types of energy […]